Background: Epigenetic alterations, such as histone methylation, modulate Myc signaling, a pathway central to oncogenesis. We investigated the role of the histone demethylase KDM4B in N-Myc-mediated neuroblastoma pathogenesis.
article
H3K27 methylation (repressive mark), is characteristic of Mycbinding sites (6) , which is consistent with recent studies that transcriptionally active epigenetic modifications mark genomic occupancy of Myc (7) (8) (9) . An emerging theory is that Myc acts as a transcriptional amplifier, increasing transcription of genes that are already turned on, while genes not actively being transcribed are unaffected (8, 9) . However, two recent papers clearly demonstrated that Myc is also able to repress transcription (10, 11) . Nevertheless, Myc appears to be required for the induction and maintenance of normal histone methylation patterns associated with active chromatin in certain settings (12) . Genetic disruption of MYCN in neural progenitors alters histone modifications that result in an increase in repressive H3K9me2/me3 marks and heterochromatinization, decreased DNA accessibility, and, ultimately, silencing of genes involved in Myc signaling (12) , suggesting that Myc is required to maintain a euchromatin configuration by modifying histone methylation to facilitate its function. Similar results have been shown in cancer cells in which 12-hour inactivation of c-Myc resulted in global chromatin remodeling including elevated H3K9me3 (13) . However, how H3K9me3/ me2 is involved in mediating Myc function is not well understood. Additionally, the genetic alteration at glycine 34 (G34) of histone H3F3A, which is believed to affect the adjacent H3K36 methylation-related function, results in statistically significant N-Myc expression in pediatric glioblastoma (14) , further supporting the biological connection between Myc activity and histone methylation.
The JmjC domain-containing histone demethylases, which are responsible for reversing most of the histone methyl marks in the human genome, play important roles in a number of physiologic processes such as stem cell maintenance, cell cycle regulation, and oncogenesis (15) (16) (17) (18) . Besides somatic mutations identified in the genes encoding histone demethylases such as UTX (19, 20) and JARID1C (21) , aberrant expression of histone demethylases has been observed in various cancers (16, 18) . KDM4B/JMJD2B and KDM4C/JMJD2C, which catalyze the demethylation of the repressive H3K9me3/me2 mark, are amplified in medulloblastoma (22) , malignant peripheral nerve sheath tumor (23) , and squamous cell carcinoma (24) , suggesting a role in the pathophysiology of these tumors. However, the contribution of these histone demethylases to the activity of oncogenic drivers such as Myc is uncertain. Additionally, the opportunity to exploit this relationship as a therapeutic strategy has yet to be explored.
Methods

Affymetrix Microarray Analysis
RNA was extracted from SK-N-BE2 and NB-1691 cells 72 hours after transfection with two different siRNA oligos (siKDM4B#1, siKDM4B#2; siMYCN#1, siMYCN#2, sequence information is in the Supplementary Methods, available online). siRNA controls were purchased from Dharmacon (siKDM4B) and Origene (siMYCN), respectively. After quality control with Agilent RNA analyzer, RNA was subjected to hybridization using an Affymetrix HT HG-U133+ PM 16-Array Plate.
RNA and miRNA Extraction and Real-Time Polymerase Chain Reaction
RNA was extracted using RNeasy Mini Kit from Qiagen, while miRNA was extracted using miVana kit from Life Technologies. Real-time polymerase chain reaction (RT-PCR) was performed using Applied Biosystems' 7500 Real-Time PCR system. The results were analyzed using delta delta Ct methods.
Data Mining
KDM4B gene expression data were downloaded from Oncomine (www.oncomine.com) or R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) and the R2 program was used to generate a Kaplan-Meier survival curve (http://r2.amc. nl). Correlation of KDM4B and MYCN was done using Spearman Correlation Analysis in the Prism program after downloading data from microarray datasets. We scanned for the optimal cutoff level of KDM4B expression and found a statistically significant difference in survival. As this is a multiple-testing approach, the P values were corrected by Bonferoni correction.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed according to the manufacturer's protocol (Magna EZ-CHIP, Millipore). Details are described in the Supplementary Methods (available online). For primers of Myc binding sites and nonbinding sites, we referred to the Myc ChIP-sequencing data in human embryonic stem cells from the ENCODE project (http://genome. ucsc.edu/ENCODE/).
Mouse Experiments
All murine experiments were done in accordance with a protocol approved by the Institutional Animal Care and Use Committee of St. Jude Children's Research Hospital. SK-N-BE2 and NB-1691 cells with shRNA knockdown of KDM4B were used to establish subcutaneous xenografts in four-to six-week-old male CB-17 severe combined immunodeficient mice (Taconic, Hudson, NY), with 5 mice for each group.
Statistical Analysis
GraphPad Prism software was used for data treatment and statistical analysis. All graph values represent means ± SD between two groups and were analyzed with the unpaired two-sided Student's t test. A P value of less than .05 was considered statistically significant. The Kaplan-Meier method was used to estimate survival curves, and the log-rank test was used to test for differences between curves. All statistical tests were two-sided.
Microarray Deposition
The microarray data have been submitted in the GEO repository with accession numbers of GSE45969 and GSE45970.
Results
Assessment of the Functional Association of KDM4B With Myc in Neuroblastoma
Given the increasing appreciation for the role of epigenetic alterations in cancer and the ability of Myc to reprogram chromatin modification, we hypothesized that histone demethylases might be involved in the pathogenesis of neuroblastoma, an aggressive cancer of childhood in which dysregulated Myc signaling has a clear role in its pathogenesis. Spearman correlation analysis of article many MYCN-correlated genes in our neuroblastoma microarray dataset showed that expression of 10 out of 17 human JmjC histone demethylases was associated with MYCN expression ( Figure 1A ), suggesting that the activity of N-Myc may be coordinated by histone demethylation. KDM4 family member KDM4B had the most statistically significant positive correlation with MYCN (R = 0.396, P < .001; Figure 1A ) (R = 0.515, P < .001; Figure 1B ), while KDM4A/JMJD2A and KDM4C/JMJD2C were negatively correlated with MYCN (R = -0.217, P = .04 and R = -0.286, P = .006, respectively) ( Figure 1A ). Separate analyses revealed that KDM4B expression was statistically significantly higher in MYCN-amplified tumors (P < .001, P = 0.01, respectively) ( Figure 1 , C and D) and that KDM4B expression was correlated with MYCN expression in various other cancers such as glioma, pancreatic adenocarcinoma, and sarcoma (Supplementary Figure 1A , available online).
To assess KDM4B function, we analyzed the global gene expression profile after a 72-hour depletion of KDM4B in two MYCN-amplified neuroblastoma cell lines, SK-N-BE2 and NB-1691 ( Figure 1E ). Gene set enrichment analysis (GSEA) (25) revealed that genes regulated by KDM4B were statistically significantly associated with the Myc signaling pathway, among 3403 gene sets (P < .001) ( Table 1 , available online). GSEA showed that genes regulated by KDM4B were statistically significantly enriched with this MYCN signature (Rank #1, P < .001) ( Figure 1I ; Supplementary Figure 1B 
Assessment of the Physical Interaction of KDM4B and N-Myc
The finding that KDM4B depletion impaired N-Myc signaling without affecting N-Myc expression at a 72-hour time point prompted us to examine the mechanism whereby KDM4B regulated Myc activity. Histone demethylases such as LSD1 and KDM4B have been shown to interact with oncogenic transcription factors such as the estrogen receptor in breast cancer (26, 27) , presumably facilitating their transcriptional activities. To assess whether KDM4B was able to interact with N-Myc, we exogenously expressed KDM4B and N-Myc to perform reciprocal immunoprecipitation and showed that KDM4B and N-Myc did physically interact (Figure 2A ). Endogenous KDM4B and N-Myc/ Max were also found to be physically associated in SK-N-BE2 cells ( Figure 2B ). We further detected the physical interaction of N-Myc and KDM4B in primary human neuroblastoma xenografts ( Figure 2C KDM4B is composed of JmjN and JmjC domains, two PHD domains, and a tandem Tudor domain ( Figure 2E ). We used immunoprecipitation to map which domain(s) of KDM4B interact with N-Myc. We found that not only was the PHD/Tudor domain able to interact with N-Myc but also with the JmjC domain was as well, although the JmjC domain showed a much weaker interaction ( Figure 2F ). Interestingly, both PHD and the adjacent Tudor domains are required for the interaction of KDM4B and N-Myc, as they interacted only weakly when tested separately ( Figure 2G ). The interaction of N-Myc and the KDM4B PHD/Tudor domains was further validated using fluorescence resonance energy transfer (FRET) (Supplementary Figures 2C and  3C , available online). We next mapped which domain of N-Myc interacted with KDM4B by using deletion mutants ( Figure 2H ) (28) . Immunoprecipitation assay revealed that KDM4B did not interact with the C-terminal basic helix-loop-helix leucine zipper (bHLH LZ) domain that dimerizes with MAX for DNA binding (Figure 2, I and J). The N-terminal transactivation domain (TAD) with MYC box I and II (MBI and MBII) was also not important for the interaction (Figure 2, I and J) . Thus, the region between amino acid 96 and 300 that contains the acidic central region of N-Myc was mapped to interact with KDM4B ( Figure 2, H-J) . Taken together, these data demonstrate that KDM4B physically interacts with N-Myc, supporting the role of KDM4B in regulation of N-Myc signaling.
The Effect of KDM4B on Histone Methylation of N-Myc Target Genes
We next assessed whether KDM4B was able to bind N-Myc responsive genes in MYCN-amplified neuroblastoma cells using ChIP-PCR. KDM4B bound to the same region of the miR-17-92 gene cluster (MIR17HG/OncomiR-1), CDC25A, TRIP13, and VCAN as N-Myc (BS) ( Figure 3A) . Correspondingly, the H3K9me3/me2 levels were much lower than the nonbinding sites (NS) of N-Myc, KDM4B, and RNA polymerase II ( Figure 3A) . These data further indicate the interaction of KDM4B and N-Myc on the genomic locus. This finding is consistent with a recent study in murine embryonic stem cells, which showed that KDM4B interacts with Myc and that they co-occupy a subgroup of genes (29) . Loss of KDM4B resulted in an increase of the H3K9me3/me2 repressive marks on the promoter of MIR17HG and a decrease in RNA polymerase II binding and acetyl H3K9 (Supplementary Figure 4A , available online), which are indicative of transcription reduction. These data demonstrate that KDM4B is able to modulate the histone methylation of Myc binding sites, thereby regulating gene expression.
We used an inducible N-Myc cell line, MYCN3, to assess whether N-Myc is able to recruit KDM4B to its binding sites, because KDM4B knockdown did not affect N-Myc binding (Supplementary Figure 4B , available online). N-Myc expression was increased after a 24-hour induction period with doxycycline (Supplementary Figure 4C , available online). The binding of N-Myc to its responsive genes, including MIR17HG, CDC25A, and VCAN occurred concomitantly with induction of N-Myc ( Figure 3B ). KDM4B binding to these genes increased at N-Myc binding sites but not the control nonbinding sites ( Figure 3B ), suggesting that induced N-Myc recruits KDM4B to the E box region. Concomitantly, H3K9me3 levels on Myc targets were decreased after normalizing to total histone H3 ( Figure 3B ). Because previous biochemical studies have indicated that KDM4 members are able to demethylate H3K36me3/me2 (30), we also assessed the H3K36me3 enrichment at these loci after N-Myc induction. The results showed that N-Myc induction increased H3K36me3 enrichment (Supplementary Figure 4D , available online), contrary to the expected action of KDM4B, suggesting a KDM4B-independent effect. Thus, our data indicate that the binding of N-Myc results in recruitment of KDM4B that subsequently remodels the regional chromatin through H3K9 methylation.
The Effect of KDM4B on Cell Proliferation, Differentiation, and Tumor Growth
To assess whether KDM4B is important for neuroblastoma cell growth, we used two different shRNAs for stable knockdown of KDM4B. Loss of KDM4B greatly reduced proliferation of MYCNamplified (SK-N-BE2, NB-1691, IMR-32, NB-1643) and c-Myc overexpressed (SK-N-AS) cells (P < .001) (Figure 4 , A-C, and data not shown). To exclude the possibility of off-target effects of shRNA knockdown, we introduced shRNA-resistant KDM4B back into cells, which statistically significantly rescued cell viability (P < .001), indicating that the observed effect is KDM4B specific ( Figure 4D ). Additionally, loss of KDM4B resulted in cell morphology changes such as neurite outgrowth, especially in SK-N-BE2 and NB-1643 cells ( Figure 4E; Supplementary Figure 5A , available online), suggestive of induction of differentiation, consistent with upregulation of differentiation marker genes ( Figure 4F ; Supplementary Figure 5B , available online). We next studied article whether KDM4B is required for tumor growth using xenograft models. Neuroblastoma cell lines were generated with stable knockdown of KDM4B using lentiviral-mediated shRNA. Depletion of KDM4B statistically significantly delayed tumor growth of these neuroblastoma xenografts (5 mice/group; P < .001) (Figure 4, G and H) . To test whether KDM4B is important in tumor maintenance, we made inducible shRNA-KDM4B in SK-N-BE2 cells in which KDM4B was efficiently reduced after Figure 4I ). The results showed that growth of established tumors was statistically significantly suppressed by inducible knockdown of KDM4B (5 mice/group, P < .001) (Figure 4I ), indicating that KDM4B is required for tumor maintenance.
The Prognostic Value of KDM4B in Neuroblastoma
We further examined the clinical relevance of KDM4B expression in neuroblastoma. The gene transcriptome data from human neuroblastoma showed that KDM4B was highly expressed in neuroblastoma (NB) in comparison with well-differentiated ganglioneuroblastoma (GNB) and ganglioneuroma (GN) (122 cases, P < .001) ( Figure 5A ). KDM4B was also expressed at higher levels in stage 4 neuroblastoma than in stage 1 (35 cases, P = .04) ( Figure 5B ). Patients with recurrent neuroblastoma also had a higher expression of KDM4B (88 cases, P = .02) (Supplementary Figure 5C, available online) . Importantly, high expression of KDM4B was associated with very poor prognosis in neuroblastoma (122 cases, P < .001) ( Figure 5C ). Even in patients with limited follow-up of five years (or deceased earlier), high KDM4B was still associated poor prognosis (122 cases, P < .001) (Supplementary Figure 5D, available online) . However, when a Cox proportional hazard analysis on the separation calculated in the Kaplan scan was performed, the KDM4B high group lost their prognostic value (Supplementary Figure 5E , available 
Discussion
Epigenetic silencing of tumor suppressor genes by DNA methylation has a well-documented role in tumorigenesis (31) . Accumulating evidence now suggests that deregulation of histone lysine methylation is also involved in cancer pathogenesis (17) , because histone methylation regulates chromatin structure and gene transcription (32) . As an important oncogenic transcriptional factor, Myc cooperates with epigenetic modulators for its full activity (33) . Here we show that KDM4B, a H3K9me3/me2 demethylase, is highly expressed in MYCN-amplified neuroblastomas with poor outcome and is a novel protein-protein interaction partner of N-Myc. We have found that the PHD and Tudor domains of KDM4B cooperatively interact with N-Myc, which resembles the interaction of KDM4A and the androgen receptor (34) , suggesting that the PHD and Tudor domains in KDM4B, like those in UHRF1, act together as a functional module in protein-protein interactions (35, 36) . Genetic ablation of KDM4B in MYCN-amplified neuroblastoma cells results in downregulation of important cancer genes such as MIR17HG, CDC25A, SOX2, KITLG, VCAN, and SDC1 that are also N-Myc targets. MIR17HG, the Oncomir-1/miR-17-92 cluster host gene, is a well-known Myc target and plays an important role in tumorigenesis including in neuroblastoma (2, 37, 38) . CDC25A is an oncogenic phosphatase required both for progression through mitosis and for Myc-induced apoptosis (39, 40) . KITLG and SOX2 are pluripotent stem cell markers (41) , and SOX2 has been shown to control tumor initiation and cancer stem article cell functions (42) . VCAN and SDC1 encode sulfate proteoglycan proteins that are involved in tumor angiogenesis (43, 44) . Thus, KDM4B plays an important role in regulation of genes that are involved in tumorigenesis and progression. Interestingly, the functions of N-Myc in the regulation of RNA metabolism seemed not to be affected by KDM4B, which is indicative of the specificity of KDM4B function. Inhibition of KDM4B primarily suppresses Myc function, inhibits neuroblastoma cell proliferation, induces cell differentiation, and delays tumor growth, indicating that targeting KDM4B may provide a new therapeutic approach for tumors in which Myc signaling is involved in oncogenesis.
Myc appears to recruit histone methylation modifiers to facilitate its function by maintaining DNA-encompassing target genes in an open configuration. For example, in a prior study, disruption of MYCN led to increased H3K9me2/me3 and decreased DNA accessibility (12) , suggesting that N-Myc is able to maintain a euchromatin state via histone demethylases. For the first time, we provide evidence that DNA binding by N-Myc is associated with KDM4B, with which it physically interacts, thereby maintaining low levels of repressive H3K9me2/ me3 marks from chromatin loci of Myc targets such as miR-17-92. Loss of KDM4B results in elevated H3K9me3/me2 marks at N-Myc binding loci, which is indicative of transcriptional repression. Myc is able to recruit multiple components including histone acetyltransferases and ATP-dependent chromatin remodeling complexes for its activity (45) . KDM4B may collaborate with these epigenetic modifiers to enhance Myc function. Although it has been shown that KDM4 members are able to demethylate H3K36me3/me2, we failed to see reduction of H3K36me3 after N-Myc induction; instead, we observed reduced H3K9me3 but increased H3K36me3. These data indicate that N-Myc recruits KDM4B to remove H3K9me3, while elevated H3K36me3 might be KDM4B independent. H3K36me3 is important in G34 mutated glioma and is connected with N-Myc function (14) . The elevated H3K36me3 suggests that N-Myc may recruit histone methyltransferases for its activity. Crystallographic structure studies show that the H3K9me3 and H3K36me3 substrates need to assume different conformations for catalysis by KDM4A (46); thus, it is possible that KDM4B can locate at H3K9 only when interacting with N-Myc. Another possibility is that KDM4 members may have a low affinity for H3K36me3 under physiological settings, as in vitro demethylation assays reveal that H3K9me3 is a more preferred modification state for KDM4A than H3K36me3 (47) .
Although we have shown that KDM4B and N-Myc physically interact and affect N-Myc function, the global picture of the and ganglioneuroma (GN) (Versteeg dataset GSE16476). NS = not statistically significant. B) KDM4B is more highly expressed in patients with stage 4 neuroblastoma (Janoueix-Lerosey dataset, GSE12460). P values were computed by Student's t test. All statistical tests were two-sided. C) Kaplan-Meier analysis shows that high KDM4B expression stratifies very poor prognosis in neuroblastoma patients from Versteeg dataset (GSE16476) (left). Gene expression and events (green and red) are shown on the right. The P value was corrected by Bonferoni correction. article interaction of KDM4B and N-Myc on the chromatin level needs to be characterized by ChIP-seq or other approaches. The effect of KDM4B on H3K9me3 was modest and whether its catalytic function is really required for N-Myc activity needs to be further confirmed using specific KDM4B inhibitors.
In summary, our findings indicate that KDM4B plays an important role in regulation of N-Myc pathway in cancer. Pharmacological targeting of KDM4B might be an effective therapeutic approach in the treatment of neuroblastoma. Specific compounds against KDM4B are not available. However, development of KDM4B inhibitors would provide more insight into understanding basic and clinical questions in MYCN-mediated cancer. 
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